To the Editor A recent retrospective cohort analysis by Dr You and colleagues1 demonstrated that compared with clopidogrel, ticagrelor was not associated with better outcomes in patients from the US and South Korea with acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). However, there are several important discrepancies between this cohort analysis and the randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.2
Kim HK, Kubica J, Jeong Y. Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention. JAMA. 2021;325(9):890. doi:10.1001/jama.2020.26020
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.